|Mr. Robert I. Blum||CEO, Pres & Director||905.58k||N/A||1964|
|Mr. Ching W. Jaw||Sr. VP & CFO||549.19k||N/A||1963|
|Mr. David W. Cragg||Chief HR & Admin. Officer||480.61k||N/A||1956|
|Mr. Mark A. Schlossberg||Sr. VP of Legal, Gen. Counsel & Sec.||564.47k||N/A||1961|
|Dr. Fady Ibraham Malik||Exec. VP of R&D||652.43k||N/A||1964|
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274, a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; and AMG 594, a novel cardiac troponin activator that is in Phase I clinical trial. The company has strategic alliances with Amgen Inc. and Astellas Pharma Inc. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.
Cytokinetics, Incorporated’s ISS Governance QualityScore as of December 8, 2019 is 6. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 7; Compensation: 6.